Other Financings Of Public Biotechnology Companies:February 2004
Total: $1,473.08M | ||||
| ||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| | ||||
Access Pharmaceuticals Inc. (AMEX:AKC) | Private placement of stock and warrants | 1.8S and 0.45W | $9.7 | Access sold the shares at $5.40 each, and the five- year warrants are exercisable at $7.10 per share; investors included SDS Merchant Fund, Baystar Capital and WPG Farber Funds; SCO Securities LLC was placement agent (2/24) |
|
|
|
|
|
Advanced Viral Research Corp. (OTC BB:ADVR) | Private placement of stock and warrants | 120S and 15W | $12 | Advanced Viral sold 120M shares to James Dicke II and James Dicke III, and warrants to purchase 15M shares at $0.20 per share; the investment will be made in four installments of $3M each, every three months; Dicke II is chairman and CEO of Crown Equipment Corp. and a former Advanced Viral director (2/4) |
|
|
|
|
|
Alfacell Inc. (OTC BB:ACEL) | Private placement of stock and warrants | 0.379S and 0.19W | $1.5 | Alfacell issued 379,170 shares of common stock at $3.96 per share and warrants to purchase an additional 189,585 shares at $4.75 per share; the investor was an undisclosed institution (2/2) |
|
|
|
|
|
Antares Pharma Inc. (OTC BB:ANTR) | Private placement of stock and warrants | 5.1S and 1.68W | $5.1 | Antares sold shares at $1 each and warrants to buy 1.68M additional shares at $1.25 each; the deal is an add-on to a financing earlier in February; SCO Securities LLC was placement agent (2/23) |
|
|
|
|
|
Antares Pharma Inc. (OTC BB:ANTR) | Private placement of stock and warrants | 9.55S and 3.15W | $9.55 | Antares sold shares at $1 each and warrants to buy 3.15M additional shares at $1.25 each; investors included Perceptive Life Sciences Fund and SDS Merchant Fund; SCO Securities LLC was placement agent (2/10) |
|
|
|
|
|
Astralis Ltd. (OTC BB:ASTR) | Private placement of units | 10.46U | $5.23 | Astralis raised the money in two closings of a financing round, in January and February; the units, sold at about $0.50 each, consisted of one share and one warrant to purchase a share at an undisclosed price (2/19) |
|
|
|
|
|
Avant Immuno- | Private placement of stock | 8.965S | $24.65 | The shares were sold at $2.75 each to undisclosed institutional investors under an existing shelf registration statement (2/13) |
|
|
|
|
|
BioCryst Pharmaceuticals Inc. (BCRX) | Registered direct offering | 3.57S | $21.43 | BioCryst sold the shares at $6 each to institutional investors; Leerink, Swann & Co. was placement agent (2/17) |
|
|
|
|
|
Biotech Holdings Ltd. (Canada; TSE:BIO) | Private placement of stock and warrants | 1.805S and 1.805W | C$0.426 (US$0.319) | Biotech Holdings raised about US$319,000 by selling shares at prices ranging from C$0.225 to C$0.25 each; the two-year warrants are exercisable at prices from C$0.225 to C$0.375 each; most of the money came from company insiders (2/4 and 2/27) |
|
|
|
|
|
BioTime Inc. (AMEX:BTX) | Subscription rights offering | 2.99U | $4.18 | Each unit consists of one common share and half a four-year warrant for the purchase of one share at $2; the total includes shares sold to guarantors of the offer (2/11) |
|
|
|
|
|
Boston Biomedica Inc. (BBII) | Credit facility | N/A | $2.5 | The company entered a $2.5 million revolving credit and security agreement with CapitalSource Finance LLC (2/11) |
|
|
|
|
|
Chiral Quest Inc. (OTC BB:CQST) | Private placement of stock and warrants | 4.8S and 2.4W | $7.2 | Investors purchased the shares at $1.50 each, and for every two shares received a five-year warrant to purchase a share at $1.65; ThinkEquity Partners LLC, Paramount Capital Inc. and Casimir Capital LP were placement agents (2/26) |
|
|
|
|
|
Connetics Corp. (CNCT) | Private placement of stock | 3S | $60.75 | Connetics sold the shares at $20.25 each; the institutional investors participating in the deal were not disclosed (2/12) |
|
|
|
|
|
Corautus Genetics Inc. (AMEX:CAQ) | Private placement of stock and warrants | 0.252S and 0.050W | $1 | Corautus sold 251,950 shares at about $3.98 each; investors also got warrants for 50,390 shares exercisable at $6.7625 each (2/2) |
|
|
|
|
|
CuraGen Corp. (CRGN) | Sale of convertible subordinated notes | N/A | $100 | The 4% notes are due in 2011 and are convertible into CuraGen shares at $9.69 per share; investors in the private placement have an option on another $20M in notes (2/10) |
|
|
|
|
|
DUSA Pharmaceuticals Inc. (DUSA) | Private placement of stock | 2.25S | $24.75 | DUSA is selling the shares at $11 each to new and existing institutional and other accredited investors, which have an option to purchase another 337,500 shares at that price (2/27) |
|
|
|
|
|
Entropin Inc. (OTC BB:ETOP) | Private placement of stock | ND | $3.85 | InvestLinc Securities LLC acted as placement agent in the financing, details of which were not disclosed (2/18) |
|
|
|
|
|
Epoch Biosciences Inc. (EBIO) | Private placement of stock and warrants | 2.47S and 0.741W | $6.18 | Epoch sold the shares at $2.50 each, and the five-year warrants are exercisable at $3.89 per share; Reedland Capital Partners was placement agent (2/24) |
|
|
|
|
|
Generex Biotechnology Corp. (GNBT) | Private placement of stock and warrants | 1.113S and 0.278W | $1.76 | Generex sold the shares and warrants to five accredited institutional investors, which got rights to purchase the same number of units on the same terms (2/27) |
|
|
|
|
|
Incyte Corp. (INCY) | Convertible notes sale | N/A | $200M | Incyte sold $200M of 3.5% convertible subordinated notes due 2011 in a private placement; the conversion price initially was set at $11.22 per share; the institutional investors have an option to buy another $50M of notes (2/12) |
|
|
|
|
|
InterMune Inc. (ITMN) | Private sale of convertible notes | N/A | $150 | InterMune sold 0.25% convertible senior notes due 2011; the shares are convertible into stock at about $21.63 per share; purchasers have an option to buy another $20M in notes (2/11) |
|
|
|
|
|
Invitrogen Corp. (IVGN) | Private sale of convertible notes | N/A | $450 | Invitrogen sold 1.5% senior convertible notes due 2024 to institutional buyers, which have an option to buy $67.5M more in notes; the notes are convertible at $102.03 per share (2/12). |
|
|
|
|
|
Keryx Biopharmaceuticals Inc. (KERX) | Private placement of stock | 3.2S | $32 | Keryx sold the shares at $10 each; the principal investors were Deerfield Partners, Maverick Capital and T. Rowe Price, which together invested $25M (2/13) |
|
|
|
|
|
La Jolla Pharmaceutical Co. (LJPC) | Underwritten offering | 8.696S | $27.4 | Pacific Growth Equities LLC is underwriting the offering, which is being made from a shelf registration statement; the shares will be sold at $3.15 each; Pacific Growth has an option to buy another 1.3M shares to cover overallotments (2/20) |
|
|
|
|
|
MGI Pharma Inc. (MOGN) | Private placement of convertible notes | N/A | $225 | MGI sold senior subordinated convertible notes due 2024; they are convertible into common stock at $62.92 per share, a premium of about 30% at the time of the deal; the institutional buyers have an option topurchase another $35M in notes (2/26) |
|
|
|
|
|
Micrologix Biotech Inc. (Canada; TSE:MBI) | Firm- commitment underwritten deal | 5U | C$5 (US$3.71) | Canaccord Capital Corp. agreed to buy 5 million units at C$1 each, each consisting of one share and a two-year, one-half-share warrant; a full warrant entitles the holder to purchase one share at C$1.25; Canaccord has an option to purchase another 2.5M units on the same terms (2/19) |
|
|
|
|
|
NeoRx Corp. (NERX) | Private placement of stock and warrants | 1.845S and 0.923W | $9.69 | The shares were sold at $5.25 each, and the five-year warrants are exercisable at $7 per share; Reedland Capital Partners was placement agent (2/23) |
|
|
|
|
|
Northfield Laboratories Inc. (NFLD) | Registered direct offering | 0.237S | $1.37 | Investors in a registered direct offering exercised their option to purchase another 237,008 shares, bringing the offering's total to $16.4M; they have an option to purchase another 409,483 shares (2/19) |
|
|
|
|
|
Pharming Group NV (the Netherlands; OTC BB:PHGUF) | Warrants exercise | 2.385S | €3.34 (US$4.19) | Investors in a €25 financing in January exercised warrants for the purchase of another 2.385M shares at €1.40 each; investors got one-year warrants to purchase 15% more shares at €2 each (2/20) |
|
|
|
|
|
Phytopharm plc (UK; LSE:PYM) | Private placement of stock | 3.88S | £6.5 (US$11.89) | Phytopharm sold the shares at 167 pence each to institutional investors, at a discount of about 7%; Nomura International plc and Canaccord Capital (Europe) Ltd. were placement agents (2/25) |
|
|
|
|
|
ReGen Therapeutics plc (UK; LSE:RGT) | Private placement of stock | 18.18S | £0.5 (US$0.93) | ReGen placed 18.18M shares at 2.75 pence each with new and existing investors (2/12) |
|
|
|
|
|
Scolr Inc. (AMEX:DDD) | Private placement of stock and warrants | 3.207S and 0.802W | $10.4 | Scolr sold the shares at $3.25 each, and the five-year warrants are exercisable at $4.75 per share; Rodman & Renshaw Inc. was placement agent (2/24) |
|
|
|
|
|
Senesco Technologies Inc. (AMEX:SNT) | Private placement of units | 0.485U | $1.15 | Senesco sold the units consisting of one common share and a warrant to purchase half a share exercisable at $3.79 per full share; investors in a Feb. 3 financing got an additional warrant for 0.15 share to match the terms of the deal (2/13) |
|
|
|
|
|
Senesco Technologies Inc. (AMEX:SNT) | Private placement of units | 1U | $2.5 | Senesco sold 1M units consisting of one common share and a warrant to purchase 0.35 share exercisable at $3.79 per share; institutional and other accredited investors participated (2/3) |
|
|
|
|
|
Tissera Inc. (Israel; OTC BB: TSSR) | Private equity placement | ND | $1.6 | Details on the deal with private and institutional investors were not disclosed (2/20) |
|
|
|
|
|
Valentis Inc. (VLTS) | Private placement of stock and warrants | 1.7S and 0.7W | $3.5 | Valentis sold the remaining shares from a private placement, the first $6.5M of which was disclosed in December; among the investors was Perseus-Soros Biopharmaceutical Fund LP (2/4) |
|
|
|
|
|
Vion Pharmaceuticals Inc. (VION) | Private placement of stock and warrants | 13.55S and 3.39W | $35.2 | The shares were sold at $2.60 each and the warrants are exercisable at $3.25 per share; Rodman & Renshaw, the lead placement agent, also got 300,000 warrants exercisable at $3.25 (2/10) |
|
|
|
|
|
V.I. Technologies Inc. (VITX) | Private placement of stock and warrants | 0.82S | $0.9 | The company added to a January financing, which now totals $10.9M; in total it sold 11.1M shares; terms of the warrants and options involved in this part of the deal were not disclosed (2/11) |
|
|
|
|
|
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||